Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.

Authors

SALAJ Peter BRABEC Petr PENKA Miroslav POHLREICHOVÁ V. SMEJKAL Petr CETKOVSKÝ Petr DUŠEK Ladislav HEDNER U.

Year of publication 2009
Type Article in Periodical
Magazine / Source Haemophilia
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords bleeding; dose; haemophilia; inhibitors; registry; rFVIIa
Description Identifying haemophilia patients with inhibitors for clinical trials is difficult due to the limited number of patients available. Registries are therefore being established as an additional means of data collection. The aim of this study was to investigate the effect of different recombinant activated factor VII (rFVIIa; NovoSeven((R))) dose ranges and dosing schedules on the incidence of re-bleeding in haemophilia patients with inhibitors. In this retrospective, uncontrolled study, data on the bleeding patterns of adult haemophilia patients with high responding inhibitors were analysed.

You are running an old browser version. We recommend updating your browser to its latest version.

More info